{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:01:52Z","timestamp":1791896512447,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"am","delay-in-days":288,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA241191"],"award-info":[{"award-number":["R01CA241191"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA242003"],"award-info":[{"award-number":["R01CA242003"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejmech.2025.117624","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T03:18:46Z","timestamp":1744687126000},"page":"117624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Discovery of XZ338, a highly potent BCL-XL degrader"],"prefix":"10.1016","volume":"291","author":[{"given":"Xuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Thummuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daohong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-6663","authenticated-orcid":false,"given":"Guangrong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117624_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117624_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117624_bib3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117624_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117624_bib5","first-page":"6101","article-title":"An informatics approach identifying markers of chemosensitivity in human cancer cell lines","volume":"60","author":"Amundson","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117624_bib6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2025.117624_bib7","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.4155\/fmc-2018-0366","article-title":"Targeting cancer's achilles' heel: role of BCL-2 inhibitors in cellular senescence and apoptosis","volume":"11","author":"Anantram","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117624_bib8","doi-asserted-by":"crossref","first-page":"S1048","DOI":"10.1016\/j.jtho.2018.10.022","article-title":"A phase I study of novel Bcl-2\/Bcl-xL inhibitor APG-1252 in patients with advanced SCLC or other solid tumor","volume":"13","author":"Wu","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.117624_bib9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/13543776.2022.2116311","article-title":"Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins","volume":"32","author":"Pal","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.117624_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.250","article-title":"MO38-1 phase 1 study of ABBV-155\u00b1paclitaxel in relapsed\/refractory solid tumors: results in Japanese patients","volume":"34","author":"Shimizu","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.117624_bib11","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X L PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117624_bib12","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1039\/C9CC07217A","article-title":"Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X L","volume":"55","author":"Zhang","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.117624_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112397","article-title":"Discovery of IAP-Recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines","volume":"199","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117624_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216\u2014a bcl-xl-specific degrader is highly active against bcl-xl-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117624_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-022-01296-8","article-title":"Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice","volume":"9","author":"Khan","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2025.117624_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00280-022-04490-8","article-title":"Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis","volume":"91","author":"Jaiswal","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117624_bib17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1535-7163.MCT-21-0474","article-title":"Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL\u2013specific degrader DT2216","volume":"21","author":"Thummuri","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117624_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-022-01241-3","article-title":"BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers","volume":"15","author":"Khan","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.117624_bib19","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3390\/cells13060528","article-title":"PROTAC-Mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer","volume":"13","author":"Khan","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117624_bib20","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/s41467-021-27210-x","article-title":"Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity","volume":"12","author":"Lv","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117624_bib21","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1021\/acs.jmedchem.1c00517","article-title":"Discovery of a novel BCL-XL PROTAC degrader with enhanced BCL-2 inhibition","volume":"64","author":"Pal","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117624_bib22","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-024-46922-4","article-title":"Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL","volume":"15","author":"Nayak","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117624_bib23","doi-asserted-by":"crossref","first-page":"279ra240","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.117624_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10384","article-title":"Bcl-xL promotes metastasis independent of its anti-apoptotic activity","volume":"7","author":"Choi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117624_bib25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","article-title":"Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-XL inhibitor","volume":"11","author":"Wang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117624_bib26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117624_bib27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/17460441.3.9.1123","article-title":"Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein\u2013protein interaction","volume":"3","author":"Wendt","year":"2008","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117624_bib28","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117624_bib29","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/ml5001867","article-title":"Discovery of a potent and selective BCL-XL inhibitor with in vivo activity","volume":"5","author":"Tao","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117624_bib30","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1021\/jo00212a013","article-title":"Solution and flash vacuum pyrolysis of some 2, 6-disubstituted. Beta.-phenethylsulfonyl azides and of. Beta.-styrenesulfonyl azide","volume":"50","author":"Abramovitch","year":"1985","journal-title":"J. Org. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:40:32Z","timestamp":1778042432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425003897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"alternative-id":["S0223523425003897"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117624","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of XZ338, a highly potent BCL-XL degrader","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117624"}}